GLENMARK

Glenmark has shown improvement in profitability after years of margin pressure. Its branded generics business in India remains strong, while specialty pipeline in dermatology and oncology adds optionality. The US business is stabilizing with fewer regulatory issues. Investors should watch debt levels and product launches. Glenmark offers turnaround potential in the pharma space for patient investors.